LDS/Medical Tests/Cohen Syndrome Mutation Genetic Analysis

Cohen Syndrome Mutation Genetic Analysis

Cohen Syndrome is a rare autosomal recessive disease associated with mutations in the VPS13B gene (also known as the COH1 gene, and Vacuolar Protein Sorting 13 homolog B gene) located on chromosome 8q22.2. Fewer than 1,000 individuals have been diagnosed with Cohen Syndrome worldwide and the incidence is unknown, but many patients will subtle phenotype probably are undiagnosed. The disorder is over-represented in the Finnish population. The COH1 protein has no known homologies to other mammalian proteins. Current studies suggest that COH1 codes for a Golgi-associated matrix protein necessary for Golgi integrity and results in abnormal protein glycosylation and endosomal-lysosomal trafficking.

The effects of COH1 dysfunction on Golgi functionality and mechanism of the development of abnormalities associated with this defect still remain unclear. Features of Cohen syndrome include developmental delay, intellectual disability, microcephaly, hypotonia, truncal obesity during adolescence, myopia, retinal dystrophy, hypermobility of joints, neutropenia and distinctive facial features. Expression of these features varies widely among patients. The genetic testing used to detect VPS13B mutation is used for carrier screening and diagnosis of disease. Affected patients can be either homozygous or compound heterozygotes.

  • To confirm/establish a diagnosis of Cohen Syndrome for individuals with features suggestive of Cohen Syndrome
  • Carrier screening for at-risk individuals with prior identification of a familial disease causing mutation
  • Prenatal and preimplantation genetic diagnosis (PGD) for at-risk pregnancies with prior identification of a familial disease causing mutation
Heterozygous mutation on VPS13B (COH1) gene would confirm a carrier. Carriers are not at risk of developing the disorder. Homozygous and compound heterozygous mutation would confirm diagnosis. Other mutations, including deletion and translocations, would also confirm diagnosis. Because the mutations in VPS13B (COH1) are distributed throughout the gene, only sequencing of the entire gene can confirm a diagnosis of Cohen Syndrome Mutations or deletions in VPS13B can be detected in 88% of individuals with typical clinical characteristics of Cohen Syndrome.

Negative for mutation analyzed (Mutation not detected)

Targeted mutation analysis, deletion/duplication analysis, sequence analysis of coding and intronic regions, whole genome array, capillary sequencing, exon array CGH.

Whole blood collected in EDTA (lavender top) tube. 

Stability

  • Room: 5 days
  • Refrigerated: 7 days
Prader-Willi and syndrome genetic testing, Cri-du-chat syndrome, Granulocyte-colony stimulating factor (G-CSF) if neutropenia is documented, Physical exam, ophthalmologic evaluation, complete blood count (CBC) with differential, Comprehensive metabolic panel, Obesity panel, chromosomal analysis, liver profile, genetic counseling.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login